Given the absence of approved therapies for NAFLD-fibrosis, it would be reasonable to initiate specific randomized controlled trials with statins (Metabolism – Clinical and Experimental)
Diabetes News
Tag: statin
Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin‐Controlled LDL Cholesterol
Despite statin‐controlled LDL‐C levels, CV events were greater among patients with diabetes and high TG levels. Because we controlled for cardiometabolic risk factors, it is likely that the difference in TG levels contributed to the excess risk observed in patients with high TGs (Diabetes, Obesity and Metabolism)
Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy
More studies of combined Metformin–statin treatment in patients are necessary to explain the effects of different Metformin–statin doses on the glucose and lipid metabolism, in different stages of progression of diabetes and/or dyslipidemia, in more detail (Cardiovascular Diabetology)
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial
Statin therapy is safe in patients with prediabetes/T2DM and NASH. Given their high cardiovascular risk, statin therapy should be encouraged in this population (JCEM)
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater (JAMA)
Use of statins offsets insulin-related cancer risk
The use of statins offsets insulin-related cancer risks in patients with diabetes independently of sex and age (Journal of Internal Medicine)
Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study
These findings suggest that, in a real clinical setting, moderate-intensity statin treatment is ineffective in cardiovascular primary prevention for patients with diabetic nephropathy (Cardiovascular Diabetology)
Interpretation of the evidence for the efficacy and safety of statin therapy
This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes (Lancet)
Statins for people with type 1 diabetes: when should treatment start?
A large evidence base supports the use of statins in people with type 2 diabetes, but there is very limited evidence for the use of statins in people with type 1 diabetes. Cardiovascular expert, Miles Fisher examines the confusion and contradictory recommendations from major guidelines, highlights the lack of new data and suggests a pragmatic approach based upon the existing research (Practical Diabetes)
Intensity of statin therapy and new hospitalizations for heart failure in patients with type 2 diabetes
In type 2 diabetes, moderate-intensity statins, in comparison to low-intensity or no statin, were associated with lower HF incidence independently of LDL levels or of CAD events (BMJ)
Statins are Independently Associated with Increased HbA1c in Type 1 Diabetes–The Thousand & 1 Study
In T1DM, use of statins is independently associated with impaired glycemic control. A causal relationship cannot be determined from this study. Given the benefit on cardiovascular outcome, this should not cause patients to stop statin treatment, but may indicate a need to revisit dose of insulin when starting statin treatment (Diabetes Research and Clinical Practice)
Statins and the Risk of Pancreatic Cancer in Type 2 Diabetic Patients – A Population-Based Cohort Study
Statin use may be associated with a reduced risk of pancreatic cancer in type 2 diabetic patients. More research is needed to clarify this association (International Journal of Cancer)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
When added to statin therapy, Ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit (NEJM)
Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study
In a population based cohort of older people with no history of vascular events, use of statins or fibrates was associated with a 30% decrease in the incidence of stroke (BMJ)
Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort
Statin treatment increased the risk of type 2 diabetes by 46%, attributable to decreases in insulin sensitivity and insulin secretion (Diabetologia)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab (NEJM)
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I)
Despite high-dose rosuvastatin lowering plasma lipid concentrations to a greater extent than did high-dose atorvastatin, atorvastatin seems to have more renoprotective effects for the studied chronic kidney disease population (The Lancet Diabetes & Endocrinology)
Glycosmedia is also available as an App: